{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T21:49:14Z","timestamp":1791841754078,"version":"4.3.4"},"reference-count":19,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T00:00:00Z","timestamp":1627516800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"abstract":"<jats:p>With increasing geographic spread, frequency, and magnitude of outbreaks, dengue continues to pose a major public health threat worldwide. Dengvaxia, a dengue live-attenuated tetravalent vaccine, was licensed in 2015, but post hoc analyses of long-term data showed serostatus-dependent vaccine performance with an excess risk of hospitalized and severe dengue in seronegative vaccine recipients. The World Health Organization (WHO) recommended that only persons with evidence of past dengue infection should receive the vaccine. A test for pre-vaccination screening for dengue serostatus is needed. To develop the target product profile (TPP) for a dengue pre-vaccination screening test, face-to-face consultative meetings were organized with follow-up regional consultations. A technical working group was formed to develop consensus on a reference test against which candidate pre-vaccination screening tests could be compared. The group also reviewed current diagnostic landscape and the need to accelerate the evaluation, regulatory approval, and policy development of tests that can identify seropositive individuals and maximize public health impact of vaccination while avoiding the risk of hospitalization in dengue-naive individuals. Pre-vaccination screening strategies will benefit from rapid diagnostic tests (RDTs) that are affordable, sensitive, and specific and can be used at the point of care (POC). The TPP described the minimum and ideal characteristics of a dengue pre-vaccination screening RDT with an emphasis on high specificity. The group also made suggestions for accelerating access to these RDTs through streamlining regulatory approval and policy development. Risk and benefit based on what can be achieved with RDTs meeting minimal and optimal characteristics in the TPP across a range of seroprevalences were defined. The final choice of RDTs in each country will depend on the performance of the RDT, dengue seroprevalence in the target population, tolerance of risk, and cost-effectiveness.<\/jats:p>","DOI":"10.1371\/journal.pntd.0009557","type":"journal-article","created":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T18:22:26Z","timestamp":1627582946000},"page":"e0009557","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":18,"title":["Target product profile for a dengue pre-vaccination screening test"],"prefix":"10.1371","volume":"15","author":[{"given":"Noah","family":"Fongwen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annelise","family":"Wilder-Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duane J.","family":"Gubler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0520-1544","authenticated-orcid":true,"given":"Eng Eong","family":"Ooi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edsel Maurice","family":"T. Salvana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"de Lamballerie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piero L.","family":"Olliaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosanna W.","family":"Peeling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,7,29]]},"reference":[{"issue":"7446","key":"pntd.0009557.ref001","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nature12060","article-title":"The global distribution and burden of dengue","volume":"496","author":"S Bhatt","year":"2013","journal-title":"Nature"},{"issue":"10169","key":"pntd.0009557.ref002","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S0140-6736(18)32560-1","article-title":"Dengue.","volume":"393","author":"A Wilder-Smith","year":"2019","journal-title":"Lancet"},{"issue":"8","key":"pntd.0009557.ref003","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taz072","article-title":"Imported dengue in Spain: a nationwide analysis with predictive time series analyses.","volume":"26","author":"L Redondo-Bravo","year":"2019","journal-title":"J Travel Med."},{"issue":"7","key":"pntd.0009557.ref004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jtm\/taz062","article-title":"Severe dengue in travellers: pathogenesis, risk and clinical management.","volume":"26","author":"S Halstead","year":"2019","journal-title":"J Travel Med"},{"issue":"4","key":"pntd.0009557.ref005","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa1800820","article-title":"Effect of dengue serostatus on dengue vaccine safety and efficacy","volume":"379","author":"S Sridhar","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"pntd.0009557.ref006","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1016\/S1473-3099(18)30494-8","article-title":"Deliberations of the Strategic Advisory Group of Experts on Immunization on the use of CYD-TDV dengue vaccine","volume":"19","author":"A Wilder-Smith","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"36","key":"pntd.0009557.ref007","doi-asserted-by":"crossref","first-page":"5137","DOI":"10.1016\/j.vaccine.2019.07.016","article-title":"Pre-vaccination screening strategies for the use of the CYD-TDV dengue vaccine: A meeting report","volume":"37","author":"A Wilder-Smith","year":"2019","journal-title":"Vaccine"},{"issue":"7","key":"pntd.0009557.ref008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pntd.0007482","article-title":"Model-based assessment of public health impact and cost-effectiveness of dengue vaccination following screening for prior exposure.","volume":"13","author":"G Espa\u00f1a","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"issue":"8","key":"pntd.0009557.ref009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jtm\/taz078","article-title":"Evaluation of rapid diagnostic tests and conventional enzyme-linked immunosorbent assays to determine prior dengue infection.","volume":"26","author":"M Bonaparte","year":"2019","journal-title":"J Travel Med."},{"key":"pntd.0009557.ref010","first-page":"1","article-title":"Immunization, Vaccines and Biologicals","volume":"2014","author":"TV Product","year":"2011"},{"key":"pntd.0009557.ref011","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jviromet.2018.03.007","article-title":"Development of an anti-dengue NS1 IgG ELISA to evaluate exposure to dengue virus","volume":"257","author":"EJM Nascimento","year":"2018","journal-title":"J Virol Methods"},{"issue":"3","key":"pntd.0009557.ref012","doi-asserted-by":"crossref","first-page":"114918","DOI":"10.1016\/j.diagmicrobio.2019.114918","article-title":"Evaluation of dengue serological tests available in Puerto Rico for identification of prior dengue infection for prevaccination screening","volume":"96","author":"M Bonaparte","year":"2020","journal-title":"Diagn Microbiol Infect Dis"},{"key":"pntd.0009557.ref013","article-title":"Accuracy and efficacy of pre-dengue vaccination screening for previous dengue infection with five commercially available immunoassays: Retrospective analysis of Phase III efficacy trials","author":"CA DiazGranados","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"pntd.0009557.ref014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jtm\/taz092","article-title":"Dengue pre-vaccination serology screening for the use of Dengvaxia\u00ae.","volume":"26","author":"E Hunsperger","year":"2019","journal-title":"J Travel Med"},{"issue":"6","key":"pntd.0009557.ref015","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1017\/S0266462319000680","article-title":"Cost effectiveness of dengue vaccination following pre-vaccination serological screening in Sri Lanka.","volume":"35","author":"S Perera","year":"2019","journal-title":"Int J Technol Assess Health Care"},{"issue":"157","key":"pntd.0009557.ref016","article-title":"Serostatus testing and dengue vaccine cost-benefit thresholds","volume":"16","author":"CAB Pearson","year":"2019","journal-title":"J R Soc Interface"},{"key":"pntd.0009557.ref017","unstructured":"World Health Organization. Report of the first meeting of the WHO Diagnostic Technical Advisory Group for neglected tropical diseases. Geneva; 2019. p. 30\u20131. Available from: https:\/\/www.who.int\/neglected_diseases\/resources\/9789240003590\/en\/."},{"issue":"10","key":"pntd.0009557.ref018","doi-asserted-by":"crossref","first-page":"e3171","DOI":"10.1371\/journal.pntd.0003171","article-title":"Evaluation of commercially available diagnostic tests for the detection of dengue virus NS1 antigen and anti-dengue virus IgM antibody.","volume":"8","author":"EA Hunsperger","year":"2014","journal-title":"PLoS Negl Trop Dis."},{"issue":"1","key":"pntd.0009557.ref019","doi-asserted-by":"crossref","first-page":"1398485","DOI":"10.1080\/16549716.2017.1398485","article-title":"ZikaPLAN: Zika Preparedness Latin American Network.","volume":"10","author":"A Wilder-Smith","year":"2017","journal-title":"Glob Health Action."}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0009557","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T18:22:41Z","timestamp":1627582961000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0009557"}},"subtitle":[],"editor":[{"given":"Indika","family":"Gawarammana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,7,29]]},"references-count":19,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,7,29]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0009557","relation":{},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,29]]}}}